Supplementary Information for Financial Results Q2 FY12/24

Aug. 13, 2024

To accelerate drug discovery and development of mAb
for therapeutics to overcome current medical unmet-needs

Chiome Bioscience Inc.

Agenda

1．Overview of Q2 FY12/24 “Financial results”

2．Overview of Q2 FY12/24 “Operation highlights”

Appendix.

Corporate information

Pipeline information

Overview of
Q2 FY12/24 “Financial results”

Financial results: Profit and Loss

(JPY in millions)

	Q2 FY2023	Q2 FY2024	Increase (decrease)	Main reasons for increase / decrease
Net sales	358	263	(95)	
Drug Discovery & Development	-	-	-	
Drug Discovery Support	358	263	(95)	Temporary decline in business volume due to the organizational changes within a client company
COS/SGA	1,018	844	(173)	
R&D Expense	601	446	(155)	Decrease in CMC costs, e.g., manufacturing cost of study drugs
Other costs	416	398	(18)	
Operating Loss	(659)	(581)	78	
Ordinary Loss	(662)	(563)	98	
Net Loss	(663)	(563)	99	

Financial results: Balance Sheet

(JPY in millions)

	As of Dec. 31, 2023	As of Jun. 30, 2024
Current assets	1,629	1,421
(Cash on hand in banks)	1,325	1,103
(Other current assets)	303	317
Non-current assets	122	136
Total assets	1,751	1,557
Current Liabilities	539	432
Non-current liabilities	54	54
Total liabilities	593	486
Total net assets	1,157	1,070
Total liabilities and net assets	1,751	1,557

Financial results: Cash Flows

(JPY in millions)

	Q2 FY2023	Q2 FY2024
Cash flows from operating activities	(595)	(677) *1
Cash flows from investing activities	0	-
Cash flows from financing activities	113	455
Net increase (decrease) in cash and cash equivalents	(481)	(221)
Cash and cash equivalents as of the beginning of the year	1,727	1,325
Cash and cash equivalents as of the end of the year	1,245	1,103

*1 Cash flows from operating activities

Expenses includes clinical development costs for CBA-1205 and CBA-1535, research costs for drug discovery, and SGA expenses.

Overview of
Q2 FY12/24 “Operation highlights”

Key Topics

SD (stable disease) assessment with tumor shrinkage in a Malignant Melanoma patient from the first part of CBA-1205 Phase 1 study, has been lasting for more than 36 months.

⇒ **Development possibility for indication expansion of CBA-1205 to melanoma started**

*Final analysis results yet to be completed.

In the CBA-1535 Phase I Clinical Study, a change in blood biomarkers indicating the activation of T-cells, which is the concept of this antibody, has begun to show. No development concerns on safety, only minor adverse events observed at present

The first dosing of ADCT-701 in the National Cancer Institute (NCI) Phase I study for neuroendocrine tumor commenced in July, 2024.

In the drug discovery projects, due diligence and negotiation on financial terms are ongoing with pharmaceutical companies to obtain out-licensing contracts in the current financial year

Through business alliance agreement with Kidswell Bio Corporation, we entered the new biosimilar business.
Aiming to create the third source of revenue followed by drug discovery and pharmaceutical company research support.

Operation Highlights

Drug Discovery and Development – Pipeline

CBA-1205	✓ SD (stable disease) assessment with tumor shrinkage in a Malignant Melanoma patient from the first part of CBA-1205 Phase I study, has been lasting for more than 36 months. Dosing is still ongoing. ✓ Scientific review with the investigator started on development possibility for indication expansion of this study drug to melanoma
CBA-1535	✓ The safety, T cell activation that is the concept of this study drug, and initial efficacy are evaluated by stepwise dose escalation for patients with solid tumors. ✓ No development concerns on safety, only minor adverse events observed at present.
License candidate	✓ Out-licensing activities with several drug discovery projects in preclinical stage are ongoing. ✓ Under CDAs, discussions, MTA evaluations and negotiations on financial terms are in progress.

Pipeline - Outsourced Clinical Studies

ADCT-701	✓ NCI started a Phase I clinical study for neuroendocrine tumor, and the dose to the first patient started in July 2024.

New Business

Biosimilar business	✓ Business alliance agreement with Kidswell Bio Corporation. Aiming for securing new source of revenue, entered to Biosimilar business using our company's clinical/CMC related functions.

Drug Discovery Support Business

Deals with pharmaceutical companies	✓ Net sales of ¥263 million in 2024 2Q (progress rate 36.7%, sales forecast for the current fiscal year ¥720 million. ✓ Net sales lower than the same period last year mainly due to an organizational changes within a client company. ✓ Entrustment Agreement with Takeda Pharmaceutical Company Limited, drug discovery support services implemented. ✓ Towards steady growth of this business, new negotiations to expand business opportunities are in progress.

Drug Discovery and Development - Pipeline

Outsourced Clinical Studies

Code	Target	Therapeutic Area	Basic research, Drug Discovery	Preclinical Study	Phase 1	Clinical Study Entity
ADCT-701 (LIV-1205 ADC)	DLK-1	Oncology /ADC			(NCT06041516)	National Cancer Institute

In-house developed product

★ First in class　★★ World first drug discovery modality moving into clinical phase

Code	Target	Therapeutic Area	Basic research, Drug Discovery	Preclinical Study	Phase 1	Status
★ CBA-1205 (ADCC enhanced)	DLK-1	Oncology			(jRCT2080225288)	Phase 1
★★ CBA-1535 (Tribody™)	5T4×CD3×5T4	Oncology			(jRCT2031210708)	Phase 1

License candidate and drug discovery project

Code	Target	Therapeutic Area	Basic research, Drug Discovery	Preclinical Study	Phase 1	Status
★ PCDC	CDCP1	Oncology/ADC				Licensing opportunity
PTRY	5T4×CD3×PD-L1	Oncology				Data is being obtained to prepare to stage up to clinical stage
BMAA	SEMA3A	Renal and other diseases				Licensing opportunity
LIV-2008 /2008b	TROP-2	Oncology				Licensing opportunity
PFKR	CX3CR1	Autoimmune disease				Licensing opportunity
PXLR	CXCL1/2/3/5	Oncology				Licensing opportunity
Discovery PJ/ Drug discovery research	Undisclosed	Oncology, Ophthalmology, etc.				—

As of Aug. 13, 2024

ADCT-701　Outsourced Clinical Studies

ADCT-701* (Humanized anti-DLK1 antibody ADC)	
Therapeutic Area	Liver cancer, lung cancer, neuroblastoma etc.
Origin	An Antibody Drug Conjugate (ADC) form of LIV-1205 that was licensed out to Switzerland-based ADC Therapeutics SA in September 2017.
Patent	Granted in Japan, US, EU, China etc. (Humanized anti-DLK1 antibody)

- ADCT-701 is an antibody-drug conjugate of the antibody LIV-1205 developed by Chiome and PBD* (*Pyrrolobenzodiazepine : Drug with anti-tumor properties)
- ✓ National Cancer Institute (NCI) completed IND submission in the USA, **the first dose for neuroendocrine tumor started in July 2024**.
  - Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas - Full Text View - ClinicalTrials.gov
- With the termination of the agreement, our company will reserve all rights related to anti-DLK-1 antibody. If a pharmaceutical company proceeds development of ADCT-701 using the Phase I study data by NCI, a license agreement will be concluded between the company and us.

Anti-DLK-1 antibody and its relation



CBA-1205 Phase 1 study

Duration of dosing the study drug to a patient with melanoma has exceeded 3 years
⇒ Review in progress for development potential for melanoma



Study design	First part (Dose escalation)	Second Part (Expansion part)
	Safety, tolerability, and pharmacokinetics in patients with solid tumors will be evaluated and the maximum tolerated dose is determined.	Safety, tolerability, and exploratory efficacy will be evaluated in patients with advanced and/or recurrent hepatocellular carcinoma.

・No serious adverse event reported

・SD (stable disease) assessment with tumor shrinkage in a Malignant Melanoma patient from the first part of CBA-1205 Phase I study, has been lasting for more than 36 months. Dosing is still ongoing.

↓

Discussion with the investigator for development of the study drug for melanoma.

- **1 PR(Partial Response: tumor shrinkage of 30% or more) was confirmed in hepatocellular carcinoma in the second part of the study.**
- **Manufacturing 2nd batch of study drugs to secure longer-term dosing cases.**
- **Analyzing the scientific relationship between PR cases and the dosing of the study drug to verify its therapeutic potential.**
- **Amended the enrollment criteria in the second part and extended the study period (no change in the out-licensing schedule)**

CBA-1535 Phase 1 study

The first part of CBA-1535 Phase I study is in progress



Study design

First part (single agent)

Target: Solid cancer patients

- Starting to administer a low dose in increments to find the maximum dose that can be safely administered.
- Evaluate initial drug efficacy signals

Second part (combined use with cancer immunotherapy drugs)

Target: Solid cancer patients

- Administer the dose that was confirmed to be safe in the first part in increments.
- Find the maximum dose that can be safely administered when combined with cancer immunotherapy drugs (IOs)
- Evaluate early drug efficacy signals when combined

The dosage is gradually increased. Beginning to see reactions in patients' blood, but there have been no safety concerns that would affect development so far.

Entering the biosimilars business

Through business alliance agreement with Kidswell Bio Corporation who has a proven record in the development of several biosimilar products, our company has entered the new biosimilars business. Aiming for securing new sources of revenue and solve social issues leading a reduction of social security costs.



Joint development of biosimilar products

- Effective use of management resources
- Sharing development costs
- Sharing acquired profit

Business model for biosimilar drug development



CB: Chiome Bioscience Inc.

KWB: Kidswell Bio Corporation

*1 Milestones: Income received by licensee at each milestone after out-licensing through the progress of clinical studies and others.

*2 Royalties: Income received as a percentage of the sales amount after a product is launched.

Drug Discovery Support business

- Net sales of 2Q FY12/2024 were ¥263 million.
- Net sales lower than the same period last year mainly due to an organizational changes within a client company.
- A business agreement with Takeda Pharmaceutical Company Limited which had been worked on a spot base is developed into a new entrustment agreement.

✓ Towards steady growth of this business, new negotiations to expand business opportunities are in progress.

- Forecast net sales of ¥720 million in the drug discovery support business in FY12/2024



Major clients	Contract date
Chugai Pharmaceutical Co., Ltd.	Jun. 2011
Chugai Pharmabody Research Pte. Ltd	Aug. 2012
Mitsubishi Tanabe Pharma Co., Ltd. TANABE RESEARCH Laboratories U.S.A., Inc.	Dec. 2016
Ono Pharmaceutical Co., Ltd.	Oct. 2018
Kyowa Kirin Co., Ltd.	Jul. 2019
Takeda Pharmaceutical Co., Ltd.	Feb. 2024

Image of transitioning to profitability

Transition from **investment phase to revenue phase** by out-licensing in-house products

Image of business income and expenses



*On assumption of out-licensing either CBA-1205, CBA-1535 or PCDC. On assumption of out-licensing agreement with milestone income

At the time of publication of this material, the actual out-licensing agreement terms and conditions, such as licensees and various amounts, have not yet been determined. This material was created to show the profitable image of our company.

Appendix. Corporate information

Corporate Overview

Biotech company dedicating to satisfy unmet medical needs



Mission

Shine light on unmet needs.
Bring a brighter future to patients.

Vision

Will become No. 1 biotech venture that discovers and develops antibody drugs for unmet medical needs

Management principle

- Place the highest priority on sound management and credibility and aim to become a corporation that grows with society.
- With creativity and science, develop therapeutic drugs for unmet medical needs, and contribute to the health of patients.
- Achieve successive product pipelines and improvement of corporate value through collaboration with external institutions.

■ Founded:
February 2005

■ Listed on the stock exchange:
Dec.2011
(Tokyo Stock Exchange Growth Section)

■ President and Chief Executive Officer:
Shigeru Kobayashi, M.E.

■ Location :
<Head Office and Research Laboratories>
3-12-1Honmachi, Shibuya-ku, Tokyo
<Drug Discovery Laboratories>
2-13-3 Nogawahonchou, Miyamae-ku, Kawasaki-city, Kanagawa

■ Number of Employees :
68 (As of Jun. 30, 2024)

■ Business :
Chiome Bioscience (4583.T), is a public company leveraging a proprietary monoclonal antibody generating technology, for drug discovery and development, as well as providing drug discovery supports.

Business Segment

Drug Discovery and Development Business

This is business to obtain revenues such as upfront, milestone, and royalty payments relating to out-licensing of patents of pipeline product and drug candidates, and also, income from collaborative research.
It drives our future growth.

Drug Discovery Support business

This is business to obtain revenues from antibody generation service by using platform technology that Chiome possesses to support drug discovery research at pharmaceutical companies, or for diagnostic and research purposes at academia or institutes on fee-for-service scheme.
It secures constant revenue stream.

Core competence for developing business

Technology Platform (Chiome's mAb Discovery Engine)

Existing technology

Animal immunization
proteins/cells/DNA



B cell cloning

Hybridoma

Functional evaluation

Lab-scale
mAb production

+

Unique antibody generation technology

ADLib® system



Tribody™

(Multispecific antibody
production technique)

+

Know-how/expertise

Membrane
proteins



Recombinant
proteins

Expression

Purification

Advantage

Chiome possesses antibody platforms including its proprietary technology, and extensive know-hows and experiences in protein/antibody engineering to streamline the process of drug discovery.

Promoting two businesses by using our technology platform

Drug Discovery and Development	Drug Discovery Support
Business responsible for growth	**Business that earns stable revenue**

Core technology that support 2 businesses: ADLib® System

Generating method of human antibodies in cultured cells (in vitro) without living organisms (animals)



- Generate human antibodies quicker than conventional methods
- Unlike immunization methods using individual animals, not affected by immune tolerance
- By utilizing the feature of autonomous genetic diversification, a high affinity of antibodies can be achieved in sequence
- Acquire antibodies as early as possible leads to early application for patents

Core Technology: Tribody™(Multispecific Antibody Production Technology)

Technology that enables the generation of multi-specific antibodies, each molecule has three binding sites.

What is Tribody™

There are three different antigen binding sites in one molecule, and this makes it possible to combine different functions.



Example of drug candidate substance creation using Tribody™

Example of utilization in our in-house product (CBA-1535)



Two hands firmly hold the target and pull the cancer-attacking cells close to the cancer cell with a third hand

Various applications are possible depending on the target/binding method.

Revenue Model

Drug development process and Chiome's revenue model



Drug Discovery

Revenues by licensing-out patents of pipeline product and drug candidates to pharmaceutical companies.



Drug Discovery Support

Revenues by providing services relating to antibody and protein to pharmaceutical and diagnostics company, and academia.



Major clients (DDS)	Contract date
Chugai Pharmaceutical Co., Ltd.	Jun. 2011
Chugai Pharmabody Research Pte. Ltd	Aug. 2012
Mitsubishi Tanabe Pharma Co., Ltd. TANABE RESEARCH Laboratories U.S.A., Inc.	Dec. 2016
Ono Pharmaceutical Co., Ltd.	Oct. 2018
Kyowa Kirin Co., Ltd.	Jul. 2019
Takeda Pharmaceutical Co., Ltd.	Feb. 2024

General image of revenue in the drug discovery business

As the stage progresses, the amount received in each milestone increases.



The above is the image of earnings to explain the Pharmaceutical Licensing Agreement. The actual agreements may vary in terms of the upfront payment, milestone stages and number/amounts of milestones, and royalty rate for each contract.

*1 Milestone: Income received by the licensee at each milestone after out-licensing through the progress of clinical studies and others.
*2 Royalty: Income received as a percentage of the sales amount after a product is sold (launched)

Business strategy for the future growth

Create candidate of innovative antibody drugs for unmet medical needs and pay maximum efforts to increase the corporate value by developing and licensing highly valuable antibodies.



Appendix. Pipeline information

CBA-1205 -In-house program-

First in class

CBA-1205 (Humanized afucosylated anti-DLK1 antibody)	
Origin	A humanized antibody generated by hybridoma technology in Livtech which Chiome acquired in 2015.
ADCC	GlymaxX (ProBioGen)
Therapeutic Area	Liver cancer, lung cancer, neuroblastoma etc.
Expectation	First-in-class therapeutic antibody targeting intractable cancers. Providing new therapeutics for highly malignant tumors that are without effective therapeutic drugs including hepatocellular carcinoma.
Patent	Granted in Japan, US, Europe, China etc.

Phase I clinical study

First part: Evaluate the safety in patients

- **No serious adverse reaction reported.**
- **SD (stable disease) evaluation with tumor shrinkage has been continued in a patient with Melanoma and the continuous dosing period has exceeded more than 36 months. Dosing is still ongoing.**

Second part: Evaluate the safety and efficacy of the drug in patients with hepatocellular carcinoma.

- **One PR(Partial Response) case has been confirmed and longer duration of response is expected.**

CBA-1205 First part of Phase 1 study (Safety)

No toxicity of Grade 3 or higher were observed
High level of safety was confirmed

CBA-1205 Related Adverse Events

Adverse Events (AE)	Dose (mg/kg)							Total (n=22)
	0.1 (n=3)	0.3 (n=3)	1 (n=3)	3 (n=4)	10 (n=3)	20 (n=3)	30 (n=3)	
Patients with CBA-1205 Related AEs	1	0	2	3	1	3	3	13
Grade 1-2	1	0	2	3	1	3	3	13
≧ Grade 3	0	0	0	0	0	0	0	0
Dose Limiting Toxicity	0	0	0	0	0	0	0	0
Serious Adverse Events	0	0	0	0	0	0	0	0
Death	0	0	0	0	0	0	0	0
Treatment Discontinuation	0	0	0	0	0	0	0	0

(As of Jun. 30, 2024)

Only Grade 1 (mild) or Grade 2 (moderate) study drug related adverse events were reported at each dose. No Grade 3 (severe or medically significant but not immediately life-threatening) or higher serious toxicity findings were reported. No adverse reactions that would have stopped dosing were reported, and the high safety of CBA-1205 was confirmed.

CBA-1205 Out-licensing plan



Out-licensing candidates: 2 different types

Companies looking to expand their development pipeline as early as possible

Companies focused on business feasibilities and probability of success

Main target for out-licensing

Possible points for evaluation and consideration

- 1st-in-class (original drug)
- High safety in humans
- Patents granted in major regions
- Manufacturing method established, information for clinical studies in place

- The response rate in patients
- Biomarker
- Comparison with other drugs, advantages
- Expansion of cancer types, business possibilities

Upfront payment ≦ **Upfront payment**

・Promote out-licensing activities, while conducting Phase 1 second part

・Aiming to maximize upfront payment in licensing deal by obtaining multiple PR or CR cases in HCC patients

CBA-1535 -In-house program-

CBA-1535（Humanized anti 5T4 & CD3 trispecific antibody)	
Origin	CBA-1535 is a T-cell engager, trispecific antibody, directed against the 5T4 tumor antigen, a protein found on various solid tumors and is thought to be involved in metastasis.
Therapeutic Area	Malignant mesothelioma, small cell lung cancer, non small cell lung cancer, TNBC etc.
Expectation	First-in-class therapeutic antibody with trispecific format Offer a new treatment option for a disease which has poor prognosis and where there are only a few effective treatments.
Patent	Granted in Japan, UK, US, EU China etc.

Phase I study: Dosing for patients has started in the first part for safety and initial drug efficacy evaluation.

Study sites: National Cancer Center Hospital

Shizuoka Cancer Center



PCDC　Out-licensing plan

First in class

PCDC（humanized anti-CDCP1 antibody for antibody drug conjugate）

Origin	Humanized anti-CDCP1 antibody discovered by Chiome's proprietary antibody technologies.
Therapeutic Area	Solid tumors (lung, colorectal, pancreatic, breast, ovarian etc.)
Expectation	CDCP1 is a First-in-class therapeutic target highly expressed in broad range of solid tumors, including standard-of-care resistant cases. High efficacy and safety expected from binding and toxicological profiles of the antibody.
Patent	"ANTI-CDCP1 ANTIBODY" : The international patent application is filed under the PCT.

- Promoting out-licensing activities, mainly in the field of ADC
- Progressing in contacting out-licensing candidate companies in Japan and abroad at conferences such as BIO International.

<u>Out-licensing strategy/target</u>

As the development needs for combining the ADC technology and our antibodies are in higher demand in out-licensing candidate companies, we will prioritize our out-licensing activities with companies with ADC technologies who need antibodies for ADC.

Antibody-Drug Conjugate Technology



PTRY -drug discovery project-

PTRY（humanized antibody 5T4/CD3/PD-L1 multi-specific antibodies）
Target molecules : 5T4×CD3×PD-L1

Origin	Therapeutic antibodies for cancer treatment using Tribody™ technology consisting of three binding sites. Therapeutic antibodies for cancer treatment targeting antigen-binding sites 1) solid tumor expressing 5T4, 2) T-cell engager CD3, and 3) immune checkpoint inhibitor PD-L1.
Therapeutic Area	Malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, Triple Negative Breast Cancer (TNBC) etc.
Expectation	A new study drug for patients who have not responded adequately to standard cancer immunotherapy. It is also expected to be useful in contributing to the healthcare economy by reducing drug prices.
Patent	Patent application completed



The results of the joint research with Ceinge Biotecnologie Avanzate (“Ceinge”) in Italy were published in the Journal of Experimental & Clinical Cancer Research, and Cancers.

Passariello et al. (2022). Novel tri-specific tribodies induce strong T cell activation and anti-tumor effects in vitro and in vivo. *Journal of experimental & clinical cancer research : CR, 41*(1), 269.

Manna et al. (2023). A Comparison of the Antitumor Efficacy of Novel Multi-Specific Tribodies with Combinations of Approved Immunomodulatory Antibodies. *Cancers, 15*(22), 5345

PTRY Efficacy of the drug in vivo

5T4×CD3×PD-L1 demonstrated strong anti-tumor activities

<In vivo drug efficacy data in lung cancer models> Passariello *et al. J Exp Clin Cancer Res (2022) 41:269*

53L10＝**PTRY**
（5T4×CD3×PD-L1）



Focus on development and out-licensing as a next-generation pipeline of CBA-1535

Potential applications for Tribody™

By varying combination of targets and number of binding

1) **More effective than normal antibodies are expected**
2) **Co-administration of multiple drugs⇒single drug administration (merits such as patients' QOL, healthcare economic benefits are expected)**

CBA-1535（currently in Phase 1）



Varying combination of targets and number of binding

Target other than 5T4



Next generation of CBA-1535





PFKR -Licensing-

PFKR (humanized anti-CX3CR1 antibody) target molecules: CX3CR1	
Orgin	Functional inhibitory antibody of Fractalkine (CX3CL1) reporter and a therapeutic antibody that inhibits disease progression of autoimmune neurological diseases, etc.
Therapeutic area	Secondary Progressive Multiple Sclerosis (SPMS), neurodegenerative disorder etc.
Expectation	SPMS is an intractable form of multiple sclerosis and is a disease with a need to develop high safety and effective therapeutic agents. By suppressing cytotoxic Eomes-positive CD4+T cells function which are considered directly related to lesions in SPMS (demyelination, neurodegeneration), expected to inhibit the progression of symptoms.
Patent	Patent application completed
Joint development partner(s)	National Center of Neurology and Psychiatry



CX3CR1 is a type of G protein-coupled receptor(GPCR), and its ligand, Fractalkine (CX3CL1), causes the migration of CX3CR1-expressing cells to inflammatory sites.

In cytotoxic Eomes positive CD4+T cells, which are considered directly related to lesions in SPMS (demyelination, neurodegeneration), CX3CR1 is expressed in many.

A paper suggesting that Eomes positive CD4+T cells are involved in the pathogenesis of ALS and Alzheimer's disease patients was published in March 2024 by the joint research partner.

PXLR -Licensing-

PXLR (humanized anti-CXCL1/2/3/5 antibody) Target molecules: CXCL1/2/3/5	
Origin	Functional inhibitory antibody for CXCL1/2/3/5, chemoattractant of CXCR2 expressing cell. Cancer therapeutic antibody that improves drug-resistant cancer microenvironment
Therapeutic area	Solid tumors (gastric, breast, ovarian etc.)
Expectation	Cancer cells express CXCL1/2/3/5 and attract immunosuppressor cells that cause the drug-resistant environment. Dosing PXLR antibody will reduce immunosuppressor cells. It is expected to overcome drug-resistance and inhibit the recurrence of cancers.
Patent	Patent application completed.
Joint development partner(s)	Osaka Metropolitan University

Drug resistant environment



Dosing PXLR

Weaking of drug-resistant environment



CXCL1/2/3/5 is a ligand of CXCR2, G-protein-coupled receptor (GPCR), and is involved in various tumorigenesis and formation processes. Cancer cells attract immunosuppressive cells with CXCL1/2/3/5 and create a drug-resistant environment. PXLR weakens drug resistant ability of cancer cells by binding to CXCL1/2/3/5.

BMAA -Licensing-

BMAA（Humanized anti-Semaphorin3A antibody）	
Origin	A humanized antibody generated using the ADLib® System. Demonstrated as a selective antibody possessing functional inhibitory activity through collaboration with Professor Yoshio Goshima in Yokohama City University.
Therapeutic Area	Renal and other diseases
Expectation	To be applied in a wide range of disease areas including inflammatory and CNS diseases which involve SEMA3A. Providing treatment methods for patients who do not respond to traditional therapeutics for diabetic retinopathy, which is the primary medical condition causing loss of sight in adulthood.
Patent	Granted in Japan, US and Europe etc.

- We are promoting joint research with Academia based on the data which we have obtained to date.
- The data obtained so far on Semaphorin 3A and the exploratory research data (Semaphorin family) will be used for future business development activities.

LIV-2008/2008b -Licensing-

LIV-2008 (Humanized anti-TROP2 antibody)

Therapeutic Area	Breast cancer (TNBC), lung cancer, colorectal cancer etc.
Expectation	LIV-2008 is a humanized monoclonal antibody targeting cell surface antigen "TROP-2" which is overexpressed in breast cancer, colon cancer, lung cancer and several types of solid cancers and is also expected to play a key role against the proliferation of cancer cells.
Patent	Granted in Japan, US, EU, China etc.

In vivo drug efficacy data in breast cancer models (LIV-2008)



Antibody: HuK5-70-2 & HuK5-70-2_LF
Animal model: MDA-MB-468 (Human, TNBC) /nude mouse xenograft treatment model

In vivo drug efficacy data in breast cancer models (LIV-2008b)



Antibody: HuT6-16-2 & HuT6-16-2_LF
Animal model: MDA-MB-468 (Human, TNBC) /nude mouse xenograft treatment model

Out-licensing activities for this antibody

Currently promoting out-licensing activities including investigation of therapeutic methods by combining this antibody with other technologies


Shine light on unmet needs.
Bring a brighter future to patients.
To accelerate drug discovery and development of mAb
for therapeutics to overcome current medical unmet-needs

Disclaimer

- Materials and information provided during this presentation may contain so-called “forward-looking statements.” These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements.

- Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations.

- The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.